The prolonged shutdown of Atomic Energy of Canada's (AECL) National Research Universal (NRU) reactor adversely affected the financial results for MDS of Ottawa, Ontario, for its first quarter of fiscal 2010.
For the period (end-January 31), MDS reported revenues from continuing operations of $46 million (U.S.), compared with $66 million in revenues from continuing operations in the same quarter of 2009. The company also posted a loss from continuing operations of $43 million, which includes a $33 million pretax restructuring charge.
Including discontinued operations for the first quarter of 2010, MDS reported a loss of $143 million, compared with income of $2 million in the same quarter of 2009.
Due to this year's divestitures of its MDS Analytical Technologies and MDS Pharma Services Early Stage businesses, the company's continuing operations focus solely on the MDS Nordion business.
Related Reading
MDS changes name to Nordion, March 16, 2010
MDS inks deals to sell Pharma Services units, February 12, 2010
MDS names Anderson as chairman, February 2, 2010
MDS to lay off 150 in Toronto, February 1, 2010
MDS blames isotope shortage for poor Q4, January 22, 2010
Copyright © 2010 AuntMinnie.com
